TY - JOUR
T1 - Altered expression of α-methylacyl-coenzyme A racemase in prostatic adenocarcinoma following hormone therapy
AU - Suzue, Kimiko
AU - Montag, Anthony G.
AU - Tretiakova, Maria
AU - Yang, Ximing J.
AU - Sahoo, Sunati
PY - 2005/4
Y1 - 2005/4
N2 - α-Methylacyl-coenzyme A racemase (AMACR) is a sensitive and specific tissue marker for the diagnosis of prostatic carcinoma. However, limited data are available on AMACR expression in residual prostatic carcinoma following hormone therapy. We analyzed 64 residual or recurrent prostatic adenocarcinomas following hormonal therapy for the expression of AMACR using a monoclonal antibody (P504S) to AMACR. In 20 localized cases, AMACR staining was absent in 11 (55%), 1+ in 6 (30%), and 2+ or 3+ in 3 (15%). However, in 15 metastatic cases, AMACR was absent in 1 (7%), 1+ in 3 (20%), and 2+ or 3+ in 11 (73%). None of the 29 postradiotherapy cases showed complete absence of AMACR staining: 2 (7%) were 1+, and 27 (93%) were 2+ or 3+. AMACR expression was reduced significantly in the majority of posthormonal residual carcinomas, whereas in postradiotherapy and in hormone-refractory metastatic prostatic adenocarcinoma, AMACR expression was retained. Therefore, the diagnosis of residual prostatic carcinoma after hormonal therapy using AMACR immunostaining must be interpreted with caution. Furthermore, AMACR might have a role in the recurrence of prostatic adenocarcinoma after medical therapy.
AB - α-Methylacyl-coenzyme A racemase (AMACR) is a sensitive and specific tissue marker for the diagnosis of prostatic carcinoma. However, limited data are available on AMACR expression in residual prostatic carcinoma following hormone therapy. We analyzed 64 residual or recurrent prostatic adenocarcinomas following hormonal therapy for the expression of AMACR using a monoclonal antibody (P504S) to AMACR. In 20 localized cases, AMACR staining was absent in 11 (55%), 1+ in 6 (30%), and 2+ or 3+ in 3 (15%). However, in 15 metastatic cases, AMACR was absent in 1 (7%), 1+ in 3 (20%), and 2+ or 3+ in 11 (73%). None of the 29 postradiotherapy cases showed complete absence of AMACR staining: 2 (7%) were 1+, and 27 (93%) were 2+ or 3+. AMACR expression was reduced significantly in the majority of posthormonal residual carcinomas, whereas in postradiotherapy and in hormone-refractory metastatic prostatic adenocarcinoma, AMACR expression was retained. Therefore, the diagnosis of residual prostatic carcinoma after hormonal therapy using AMACR immunostaining must be interpreted with caution. Furthermore, AMACR might have a role in the recurrence of prostatic adenocarcinoma after medical therapy.
KW - AMACR
KW - Hormone therapy
KW - Prostate carcinoma
KW - α-Methylacyl-coenzyme A racemase
UR - http://www.scopus.com/inward/record.url?scp=15744394110&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=15744394110&partnerID=8YFLogxK
U2 - 10.1309/H4JX0XEHDAC8YL3P
DO - 10.1309/H4JX0XEHDAC8YL3P
M3 - Article
C2 - 15743746
AN - SCOPUS:15744394110
SN - 0002-9173
VL - 123
SP - 553
EP - 561
JO - American journal of clinical pathology
JF - American journal of clinical pathology
IS - 4
ER -